OBJECTIVES: The Turkish Medicines and Medical Devices Agency (TMMDA) gives permission of unlicensed medicine use by patient basis. Authorized wholesalers including Turkish Pharmacists’ Association (TPA) can import the drugs based on the TMMDA`s permission. These medicines are reimbursed by the Social Security Institution (SSI), the main reimbursement agency in Turkey Until 2014 when wholesalers were also authorized, pharmaceuticals under this status could only be imported by the Turkish Pharmacists’ Association (TPA   The aim of this study is to understand the trends in L group (Antineoplastic and immunomodulating agents) of ATC classification system unlicensed medicine consumption between 2011 and 2013 when the TPA was the only authorized supplier. METHODS: Consumption data of L group in the top 100 imported unlicensed medicines with the highest sales share in total expenses of imported off-label use was taken from the TMMDA computer database. Descriptive analysis was conducted. RESULTS: The analysis showed that the numbers of active ingredients of L group in the top 100 rose from 37 to 55, between 2011 and 2013. The average cost per box of unlicensed medicines in the L group increased from 4.973 TL to 7.436 TL in the same period. The total consumption of the unlicensed medicines in L group increased from 107 billion TL to 482 billion TL. CONCLUSIONS: The cost of imported unlicensed medicines used increased every year in Turkey. Some cost-containment measures (especially for antineoplastic medicines) should be taken to reduce the increasing cost without risking the patients’ access to these innovative medicines.